近日，SINTX科技公司（SINTX Technologies Inc）宣布完成全球首例采用其经美国食品药品监督管理局（FDA）批准的Sinaptic®足踝植入系统的人体手术。这一里程碑事件标志着该创新医疗器械正式进入临床应用阶段。
该植入物专为足踝关节修复设计，采用先进生物材料技术，旨在为患者提供更优化的骨骼融合解决方案。手术的成功实施为未来相关适应症的治疗开辟了新路径。
近日，SINTX科技公司（SINTX Technologies Inc）宣布完成全球首例采用其经美国食品药品监督管理局（FDA）批准的Sinaptic®足踝植入系统的人体手术。这一里程碑事件标志着该创新医疗器械正式进入临床应用阶段。
该植入物专为足踝关节修复设计，采用先进生物材料技术，旨在为患者提供更优化的骨骼融合解决方案。手术的成功实施为未来相关适应症的治疗开辟了新路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.